Form 4: Theravance Biopharma Executive Sells Shares Under Pre-Arranged Plan

A senior executive at Theravance Biopharma, Inc. sold 10,000 ordinary shares for approximately $11.39 per share, executed under a pre-existing 10b5-1 trading plan.

Summary

• Rhonda Farnum, SVP, Commercial & Medical Affairs at Theravance Biopharma, Inc. (TBPH), sold a total of 10,000 ordinary shares.
• The sales occurred on July 14, 2025, at weighted average prices ranging from $11.3855 to $11.3927 per share.
• Specifically, 682 shares were sold at $11.3927, 5,318 shares at $11.3855, and 4,000 shares at $11.3879.
• Following these transactions, Rhonda Farnum beneficially owns 326,918 ordinary shares directly.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan established on March 14, 2024.

Sentiment

Score: 5

Explanation: Neutral. While it's an insider sale, the execution under a 10b5-1 plan mitigates negative sentiment as it's a pre-scheduled, routine transaction rather than a reactive one based on new information.

Negatives

• An insider, SVP of Commercial & Medical Affairs, sold a significant number of shares (10,000), which could be perceived negatively by some investors, although it was pre-planned.

Industry Context

This transaction is a routine insider stock sale by an executive at a biopharmaceutical company. Such sales are common for compensation and personal financial planning, especially when executed under a Rule 10b5-1 plan, which pre-schedules trades to avoid accusations of trading on material non-public information. It does not inherently reflect on broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a slight negative, though the 10b5-1 plan context often lessens this impact. It's a routine part of executive compensation and liquidity.

Key Dates

Recommendation

Keywords

Theravance Biopharma, TBPH, SEC Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Executive Compensation, Rhonda Farnum, Ordinary Shares